Maryam Aftab | Health & Medicine | FRP Academic Excellence Award

Dr. Maryam Aftab | Health & Medicine | FRP Academic Excellence Award

Assistant Professor | Rawalpindi Women University | Pakistan

Maryam Aftab’s research focuses on the design, synthesis, and biomedical applications of inorganic-based nanomaterials, with particular emphasis on wound healing and regenerative medicine. Her work explores how nanostructured materials enhance antimicrobial activity, tissue regeneration, and controlled drug delivery to improve healing outcomes. She critically examines current challenges, including biocompatibility, toxicity, and clinical translation, while identifying future opportunities for advanced therapeutic solutions. Through interdisciplinary approaches combining materials science and biomedical engineering, her research contributes to the development of innovative, efficient, and scalable nanomaterial-based strategies for next-generation wound care and healthcare applications.

Citation Metrics (Scopus)

40
30
20
10
0

Citations
31

Documents
9

h-index
3


View Scopus Author Profile

Featured Publications

Eman Abdeall | Health & Medicine | Best Researcher Award

Prof. Eman Abdeall | Health & Medicine | Best Researcher Award

Head of Department | Beni-Suef Univeristy | Egypt

Prof. Eman K. A. Abdelall is an accomplished researcher specializing in pharmaceutical organic chemistry with a focus on drug synthesis, molecular design, and structure-activity relationship studies. Her extensive research portfolio demonstrates a strong commitment to the discovery and development of bioactive compounds targeting critical human diseases. She has made significant advancements in the design and synthesis of novel molecules with anti-inflammatory, anticancer, and antiviral properties, employing a multidisciplinary approach that integrates organic synthesis, computational modeling, and biological evaluation. Her recent studies include the development of quinazolinone-based compounds as dual STAT-3 and c-Src inhibitors, the design of antipyrine-celecoxib hybrid analogues with dual COX-2 and SARS-CoV-2 Mpro inhibitory activities, and the synthesis of new pyrazoles with selective anti-inflammatory potential. Prof. Abdelall’s work, published in high-impact journals such as Bioorganic Chemistry, Bioorganic and Medicinal Chemistry Letters, and Drug Development Research, reflects her expertise in rational drug design and her ability to translate molecular innovations into pharmacologically relevant candidates. With 46 peer-reviewed publications, over 1,045 citations, and an h-index of 20, her research demonstrates both quality and global impact. Her findings contribute to understanding molecular mechanisms underlying inflammation, cancer proliferation, and viral replication, offering new therapeutic strategies with enhanced efficacy and safety. Through her sustained publication record, interdisciplinary research, and consistent scientific innovation, Prof. Abdelall has established herself as a leading contributor in pharmaceutical chemistry, advancing the field of rational drug design and synthesis with high translational value for modern medicine.

Profile: Scopus | ORCID | Google Scholar

Featured Publications

  • Abdelall, E. K. A., Lamie, P. F., Fadaly, W. A. A., & Abdelgawad, Y. Y. M. (2025). Development of novel quinazolinone-based compounds with anti-proliferative activity as dual STAT-3 and c-Src inhibitors: Design, synthesis and molecular dynamic studies. Bioorganic Chemistry, 163, 108753.

  • Abdelall, E. K. A., Elshemy, H. A. H., Labib, M. B., Philoppes, J. N., Ali, F. E. M., & Ahmed, A. K. M. (2025). Synthesis of new selective agents with dual anti-inflammatory and SARS-CoV-2 Mpro inhibitory activity: Antipyrine-celecoxib hybrid analogues; COX-2, COVID-19 cytokine storm and replication inhibitory activities. Bioorganic Chemistry, 160, (Article number not specified).

  • Abdelall, E. K. A., EL-Nahass, E. S., Abdellatif, K. R. A., Abdel-Rahman, H. M. (2021). Design, synthesis, biological assessment and in silico ADME prediction of new 2-(4-(methylsulfonyl)phenyl) benzimidazoles as selective cyclooxygenase-2 inhibitors. RSC Advances, 11, 27659.